STSA 1005
Alternative Names: STSA-1005Latest Information Update: 04 Oct 2022
At a glance
- Originator Staidson Biopharma
- Class Anti-inflammatories; Antibodies; Antivirals
- Mechanism of Action Granulocyte-macrophage colony stimulating factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I COVID 2019 infections
- Preclinical Autoimmune disorders
Most Recent Events
- 29 Sep 2022 Staidson Beijing BioPharmaceuticals plans a phase I pharmacokinetics and safety trial (Combination therapy, In adults) in China in September 2022 (IV) (NCT05559125),
- 05 Apr 2022 Staidson Biopharma completed the phase I trial in COVID-2019 infections (In volunteers) in USA (IV) (NCT05085197)
- 27 Oct 2021 Phase-I clinical trials in COVID-2019 infections (In volunteers) in USA (IV) (NCT05085197)